Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Fallopian Tube Neoplasms 10 Ovarian Neoplasms 7 Endometrial Neoplasms 5 Breast Neoplasms 4 Prostatic Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Osteosarcoma 2 Neuroendocrine Tumors 2 Neuroblastoma 2 Neoplasms 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Glioma 2 Glioblastoma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Neoplasms × olaparib × 30 days × Clear all

NCT03742895 2026-05-15

MK-7339-002

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡